AMENDMENTS TO THE SPECIFICATION

Please replace the second-to-last paragraph on page 5 of the specification with a paragraph revised as shown below:

Figure 1A-1 shows binding site peptides **(SEQ ID NOs: 49-88)** prepared based on the CD40 sequence, to which the anti-CD40 agonistic antibodies bind;

Please replace the last paragraph on page 5 of the specification with a paragraph revised as shown below:

Figure 1A-2 shows binding site peptides **(SEQ ID NOs: 89-130)** prepared based on the CD40 sequence, to which the anti-CD40 agonistic antibodies bind (a continuation to Figure 1A-1);

Please replace the first paragraph on page 6 of the specification with a paragraph revised as shown below:

Figure 1B-1 shows binding site peptides **(SEQ ID NOs: 49-88)** prepared based on the CD40 sequence, to which the anti-CD40 antagonistic antibodies bind;

Please replace the second paragraph on page 6 of the specification with a paragraph revised as shown below:

Figure 1B-2 shows binding site peptides **(SEQ ID NOs: 89-130)** prepared based on the CD40 sequence, to which the anti-CD40 antagonistic antibodies bind (a continuation to Figure 1B-1);

Please replace the paragraph that straddles page 43 and 44 of the specification with a paragraph revised as shown below:

An anti-CD40 antibody was purified from the above culture supernatant by the following method. The culture supernatant containing an anti-CD40 antibody was affinity purified in a ~~Hyper D~~ **Hyper D®** Protein A column (manufactured by NGK Insulators, Ltd.) or in case of mouse IgG1 purification, a Protein G column (Amersham Pharmacia Biotech) according to the attached instruction using PBS(-) as an adsorption buffer and a 0.1 M sodium citrate buffer (pH 3) as an elution buffer. The eluted fraction was adjusted to about pH 7.2 by addition of a 1 M Tris-HCl (pH 8.0) or Na2HPO4 solution. The prepared antibody solution was substituted with PBS(-) using a dialysis membrane (10,000 cuts, manufactured by Spectrum Laboratories, Inc.) or an SP column (Amersham Pharmacia Biotech), and filtered and sterilized using a membrane filter ~~MILLEX-GV~~ **MILLEX®-GV** with a pore diameter of 0.22 μm (manufactured by Millipore Corp.). The concentration of the purified antibody was calculated by measurement of the absorbance at 280 nm, taking 1 mg/ml as 1.450D.

Please replace the last paragraph on page 61 of the specification with a paragraph revised as shown below:

T24, Hs 766T and Capan-2 were digested with trypsin and harvested, and Ramos was harvested as is. The cell lines were washed with PBS, and then re-suspended in a staining buffer containing 1 μg/ml of 341G2Ser. The staining buffer was prepared by adding 0.05 mM EDTA, 0.05% sodium azide and 5% immobilized bovine serum to PBS. After incubation at 4°C for 15 minutes, the cells were washed with the staining buffer twice, and re-suspended in a 1:250 dilution of PE-bound goat anti-human IgG (γ) (Southern Biotechnology Associates, Inc) with the staining buffer. After incubation at 4°C for 15 minutes, the cells were washed with the staining buffer twice, and analyzed with ~~FACSCalibur~~ **FACSCalibur™** (manufactured by BD Biosciences). The same amount of a human anti-2,4-dinitrophenol (DNP) antibody was used as a negative control. The analysis was carried out using ~~Cellquest~~ **Cellquest™** (manufactured by BD Biosciences) as data analysis software to calculate the mean fluorescence intensity.